Charles R. Esther, JR.,Michael R. Knowles,Wanda Kay ONeal,Deepika Polineni,Steven Isaacman,Andrew B. Mahon
申请号：
US15943964
公开号：
US20180353511A1
申请日:
2018.04.03
申请国别(地区):
US
年份:
2018
代理人:
摘要：
This invention relates generally to the use of 5′-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
